Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00183989
Status:
TERMINATED
Last Update Posted:
2014-05-22
First Post:
2005-09-12
Brief Title:
Combination Therapy With Fludarabine Mitoxantrone and Rituximab in Mantle Cell Lymphoma
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
A Pilot Phase II Trial of Combination Therapy With Fludarabine Mitoxantrone and Rituximab in Mantle Cell Lymphoma
Status:
TERMINATED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Insufficient accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done in order to determine the effectiveness of the combination of fludarabine mitoxantrone and rituximab in patients with mantle cell lymphoma All three drugsfludarabine mitoxantrone and rituximab have been approved by the US Food and Drug Administration FDAfor the treatment of certain types of lymphoma Rituximab is a drug called a monoclonal antibody which has anti-tumor activity on certain types of lymphoma The combination of chemotherapy fludarabine and mitoxantrone with rituximab has not yet been investigated in patients with mantle cell lymphoma and therefore the combination in investigational
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None